Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates

March 10, 2022

Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting

March 8, 2022

Gritstone to Participate in Cowen 42nd Annual Health Care Conference

February 24, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 8, 2022

Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference

February 8, 2022

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 25, 2022

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

January 13, 2022

Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19

January 4, 2022

Gritstone Announces Presentations during Three Upcoming Investor Conferences

December 30, 2021

Gritstone Announces Changes to Its Board of Directors

December 17, 2021

Pagination

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

© 2024 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top